%0 Journal Article
%A Kimmich, Christoph R
%A Terzer, Tobias
%A Benner, Axel
%A Hansen, Timon
%A Carpinteiro, Alexander
%A Dittrich, Tobias
%A Veelken, Kaya
%A Jauch, Anna
%A Huhn, Stefanie
%A Basset, Marco
%A Goldschmidt, Hartmut
%A Müller-Tidow, Carsten
%A Schönland, Stefan O
%A Hegenbart, Ute
%T Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
%J American journal of hematology
%V 96
%N 7
%@ 1096-8652
%C New York, NY
%I Wiley-Liss
%M DKFZ-2021-00848
%P E253-E257
%D 2021
%Z 2021 Jul 1;96(7):E253-E257 /Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33844864
%R 10.1002/ajh.26191
%U https://inrepo02.dkfz.de/record/168354